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Aims Longevity of implantable cardioverter defibrillators (ICDs) is crucial for patients and healthcare systems as replace-
ments impact on infection rates and cost-effectiveness. Aim was to determine longevity using very large databases
of two teaching hospitals with a high number of replacements and a rather homogeneous distribution among
manufacturers.
Methods
and results
The study population consists of all patients in whom an ICDwas inserted in. All ICDmanufacturers operating in Switz-
erland and the Netherlands and all implanted ICDs were included. Implantable cardioverter defibrillator replacements
due to normal battery depletion were considered events, and other replacements were censored. Longevity was
assessed depending on manufacturers, pacing mode, implant before/after 2006, and all parameters combined. We ana-
lysed data from 3436 patients in whom 4881 ICDs [44.2% VVI-ICDs, 27.4% DDD-ICDs, 26.3% cardiac resynchroniza-
tion therapy (CRT)-ICDs, 2.0% subcutaneous ICDs] were implanted. The four major manufacturers had implant shares
between 18.4 and 31.5%. Replacement due to battery depletion (27.4%) was performed for 1339 ICDs. Patient survival
at 5 years was 80.1%. Longevity at 5 years improved in contemporary compared with elderly ICDs [63.9–80.6% across
all ICDs, of 73.7–92.1% in VVIs, 58.2–76.1% in DDDs, and of 47.1–66.3% in CRT defibrillators, all P value , 0.05].
Remarkable differences were seen among manufacturers, and those with better performance in elderly ICDs were
not those with better performance in contemporary ones.
Conclusion Implantable cardioverter defibrillator longevity increased in contemporary models independent of manufacturer and
pacing mode. Still, significant differences exist among manufacturers. These results might impact on device selection.
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Introduction
In selected patients, implantable cardioverter defibrillators (ICDs)
are considered standard of care for primary and secondary preven-
tions of sudden cardiac death.1 – 5 Devices reduce morbidity and
mortality due to efficient termination of ventricular tachyarrhyth-
mias. Yet undesired factors such as complications during and early
after implantation,3 deterioration in quality of life,4,6 lead failure,1
and advisories2 are increasingly identified. The most disturbing
element for patients, apart from repeated inappropriate shocks,7
however, is the necessity of a surgical procedure for ICD replace-
ment due to premature or even timely battery depletion. Besides
the cost of the procedure, there is the risk of periprocedural com-
plications such as damage to the leads, bleeding, and infections.8,9
During the past decade, several studies on ICD longevity have
been published.10–20 With the exception of one large series,18 all
studies included ,1300 ICDs and the number of actually replaced
ICDs was low, thus compromising the significance of the results. In
addition, analyses were performed only among different manufac-
turers, not accounting for temporal trends in longevity between
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different models. Overall, it was confirmed that single-chamber de-
fibrillators (VVI-ICDs) have better longevity than dual-chamber de-
fibrillators (DDD-ICDs) and the latter a better one than cardiac
resynchronization therapy defibrillators (CRT-Ds).
In contrast, results regarding longevity advantages of one manu-
facturer as against another were heterogeneous and sometimes
even contradictory. Nevertheless, positive results have been used
by some manufacturers for advertising campaigns in major electro-
physiological journals.
The aim of this study was to perform a comprehensive analysis of
longevity in a large series of ICDs not only with respect to different
manufacturers, but also to different device models, pacing mode and
to determine temporal trends of ICD longevity.
Methods
The study population consists of all consecutive patients in whom an
ICD was implanted at the Erasmus Medical Center, Rotterdam, the
Netherlands and at the University of Basel Hospital, Basel, Switzerland.
The implant period encompasses from March 1994 to January 2014.
Some of these patients and ICDs have already been included in two
previous studies.14,15 As this study is an analysis of all ICD implanta-
tions in both hospitals, we still considered these data for the present
study.
Baseline characteristics of the patients and details of follow-up visits
were recorded prospectively, as well as data regarding implanted ICD,
such as manufacturer, device model, and pacing mode (single chamber,
dual chamber, CRT). Date of last access to the database was 31 May
2014 for patients at the Erasmus Medical Center, Rotterdam and 30
June 2014 for patients at the University of Basel Hospital.
ICD replacements due to normal battery depletion, a so-called elect-
ive replacement indication (ERI), were considered events. Service time
in months was calculated as the difference between implant date and re-
placement date or between replacement date and replacement date, as
appropriate. In all other replacement settings such as upgrade, advisory,
or removal for infection, the device was censored at the date of the
procedure. Implantable cardioverter defibrillators still in service were
censored at the date of last database access. Implantable cardioverter
defibrillators still in service but lost to follow-up were censored at
the date of last follow-up. Implantable cardioverter defibrillators of pa-
tients who died or were transplantedwere censored at the date of these
corresponding events. Figure 1 displays a flow chart of both patients and
ICDs.
All manufacturers of ICDs ever operating in the two countries and
all their ICDs used in the two hospitals were included. These were in
alphabetical order: Biotronik (Berlin, Germany), Boston Scientific
(earlier Guidant; Marlborough, MA), Cameron Health (San Clemente,
CA), Intermedics (formerly in Le Locle, Switzerland), Medtronic (Min-
neapolis, MN), St. Jude Medical (St. Paul, MN), and Sorin (earlier ELA,
Milano, Italy).
For the purpose of this article, the term longevity is used for device
longevity and the term survival for patient survival.
The first analysis was performed across all ICDs of a given manufac-
turer, and longevity was compared. The second analysis was performed
across different pacing modes, wherefore all manufacturers were
merged and longevity was compared between pacing modes. The third
analysis was performed across ICDs according to pacing mode in
between individual manufacturers. For the fourth analysis, a ranking of
longevity at the time points 4 and 5 years was performed and a corre-
sponding chart of the best five and worst three devices was made. An
analysis across ICDs with a similar production year grouped together
was also performed here. Finally, a comparison of longevity across man-
ufacturers according to pacing mode of ICDs implanted before 2006
and thereafter was performed. This time point was chosen as it was
close to the median of all devices. No individual analyses were per-
formed in those devices with ,20 implants.
In both hospitals, an institutional review board approval was not re-
quired as the study was designed as an analysis of retrospective registry
data. Patient information was de-identified in the merged Excel file that
was used for all analyses.
Kaplan–Meier method was used to determine longevity, and differ-
ences were compared with log-rank testing. A P value of ,0.05 was
considered as statistically significant. All statistical analyses were per-
formed using IBM SPSS software, version 22.
Results
We analysed data from 3436 patients [median age 62 years (IQR
52–70)] in whom 4881 ICDs have been implanted. Important base-
line characteristics of the patients are shown in Table 1. During a
follow-up of median 53 months (IQR 24–87), 822 (23.9%) patients
died. This results in a 4-, 5-, and 10-year cumulative survival of 83.3,
80.1, and 59.1%, respectively. The corresponding Kaplan–Meier
curve (Supplementary material online, Figure S1) indicates a linear
mortality rate. Appropriate ICD therapy was delivered to 972 pa-
tients (28.3%).
Overall, 2158 (44.2%) VVI-ICDs, 1340 (27.4%) DDD-ICDs, 1284
(26.3%) CRT-ICDs, and 99 (2.0%) subcutaneous ICDs were in-
serted. In Table 2, details on manufacturers and pacing modes are
presented. The percentages of ICDs used from the different manu-
facturers in a downward frequency are as follows: St. Jude Medical
31.5%, Biotronik 25.0%, Boston Scientific 19.4%, Medtronic 18.4%,
Sorin ELA 3.2%, Cameron Health 2.0%, and Intermedics 0.4%. In
the Supplementary material online, Table S1, all ICD models are dis-
played in detail. As shown in Figure 1, 1339 ICDs were replaced for
ERI (27.4%, range 1–5 per patient) and 206 (4.6%) for other
reasons.
What’s new?
† Several studies on implantable cardioverter defibrillator
(ICD) longevity have been published. Except one, all studies
included ,1300 ICDs and the number of replaced ICDs was
low, thus compromising the significance of results. This one is
a study with the largest number of ICDs included so far.
† It shows a rather homogenous distribution of ICDs from the
four largest manufacturers (St. Jude Medical 31.5%, Biotronik
25.0%, Boston Scientific 19.4%, Medtronic 18.4%) compared
with earlier studies with much more skewed distributions.
† Previous studies showed minor differences between manu-
facturers, while this study, especially in more contemporary
ICDs, demonstrated huge differences. Longevity at 6 years
in cardiac resynchronization therapy-ICDs, e.g. was 97.6%
with the best manufacturer, compared with 46.3% with the
second best.
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Overall longevity, is shown in the Supplementary material on-
line, Figure S2. It was 85.1% at 4 years and 69.8% at 5 years. Longev-
ity before 2006 (2198 ICDs, 45%) and thereafter (2683 ICDs,
55%) was compared. These overall values at 5 and 6 years for
VVI-ICDs, DDD-ICDs, and CRT-Ds were 80.1 and 62.7, 62.0
and 43.4, and 56.3 and 27.4%, respectively. The difference accord-
ing to pacing modes before and after 2006 is depicted in the
Supplementary material online, Figure S3. Figures 2–5 show the
comparisons of longevity according to manufacturers in the two
implant periods before and after 2006, overall as well in the differ-
ent pacing modes.
Overall, cumulative longevity markedly improved from 63.9 to
80.6% at 5 years and from 44.9 to 61.6% at 6 years (P ≤ 0.001).
The same holds true for different pacing modes (all P ≤ 0.001).
On the level of manufacturers, intra- as well as intermanufactural im-
provement was diverse and occasionally even remarkable. Whereas
in the early period, usually Medtronic ICDs had the best longevity,
this changed to Boston Scientific ICDs in contemporary devices.
Boston Scientific ICDs exhibited an excellent, sometimes even
100% longevity, independent of pacing mode (see Table 3 for
more details).
The Supplementary material online, Table S2, presents the charts
of the five longest lasting and the three shortest lasting devices at the
time points of 4 and 5 years, according to pacing mode. Medtronic
held 10/30 positions in the longest lasting charts, Biotronik and
Boston Scientific both 8/18 in the shortest lasting charts. The
Supplementary material online, Tables S3 and S4, depicts longevity
of ICD with a similar year of production and a comprehensive
5-year longevity of all ICD models.
Comparing patient survival with ICD longevity, the ICDs always
performed poorer. In VVI, 5-year survival and longevity were
85.1% in patients and 80.1% in ICDs, in DDD 77.0 and 62.0%, and
in CRT 72.8 and 56.3%, respectively.
Discussion
This article represents the largest study on ICD longevity so far and
includes all major manufacturers in a reasonably balanced propor-
tion. Although all manufacturers have improved on longevity of their
devices, large differences in longevity still exist. Before 2006, Med-
tronic VVI-ICDs, Medtronic DDD-ICDs, and St. Jude Medical
CRT-Ds exhibited the best longevity. In the current era (i.e. after
2006), however, Boston Scientific ICDs outperformed all other
manufacturers with regard to longevity. In spite of these partly re-
markable improvements, survival of patients is better than ICD lon-
gevity and not vice versa as should be the case.
Comparison with other studies regarding
differences among manufacturers
Of the nine studies on overall longevity, only three provided
reliable data in a larger group of patients and devices.13,15,18
3436 patients:
1130 from basel
2306 from rotterdam
4881 ICDs:
1628 from basel
3253 from rotterdam
1545 replaced, thereof:
1339 replaced due to elective replacement
indication
98 replaced prematurely due to advisories
46 replaced prematurely due to infection
41 replaced prematurely due to system upgrade
13 replaced prematurely, e.g. during lead revision
8 replaced prematurely due to device failure
3336 in service or
censored for*
2154 are alive and in study to 5 June 2014
822 died before 5 June 2014*
85 underwent cardiac transplant*
189 were transferred to another hospital*
154 were lost to follow-up*
32 were downgraded or not replaced
Figure 1 Flow chart of patients and ICDs.
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All cover an extensive implant period of 13–21 years and there-
fore report on a vast range of ICD models. Superior longevity of
VVI pacing mode (median longevity 6–7.3 years) over DDD pa-
cing mode (5–5.7 years) and over CRT pacing mode (median lon-
gevity 4.2 –5.2 years) is consistently reported, and these
differences can be explained primarily by the increasing percent-
age of pacing. Main analyses were carried out by lumping together
all ICDs by a given manufacturer independently of pacing mode
and model. Medtronic excelled throughout with median longev-
ities from 5.8 to 7.6 years. Runners-up were Boston Scientific and
Table 1 Baseline characteristics of the 3436 patients
Male gender 2721 (79%)
Age (mean+ SD) 59+14
Follow-up (mean+ SD) 60.3+44.4
Ejection fraction (mean+ SD) 32+13
QRS width (mean+ SD) 127+35
Primary prevention 1975 (57%)
Ischaemic cardiomyopathy 2525 (74%)
Myocardial infarction 1825 (53%)
Percutaneous coronary intervention 1069 (31%)
Coronary artery bypass 769 (22%)
Diabetes mellitus 694 (20%)
Creatinine level (mmol/L, mean+ SD) 103+69
NYHA Class I 792 (23%)
NYHA Class II 1680 (49%)
NYHA Class III 907 (27%)
NYHA Class IV 39 (1%)
ACE/ARB therapy 2640 (77%)
Beta-blocker therapy 2621 (76%)
Diuretic therapy 2029 (59%)
Statin therapy 1978 (58%)
Amiodarone therapy 685 (20%)
Digoxin therapy 461 (13%)
SD, standard deviation; ACE, angiotensin converting enzyme inhibitor; ARB,
angiotensin receptor blocker.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Manufacturers, ICD, pacing modes (upper
row) and replaced ICDs (lower row), shown in
alphabetical order
Manufacturer VVI DDD CRT Total % Replaced
Biotronik 645 346 228 1219
149 126 23 298 24.5%
Boston Scientific 413 275 259 947
118 113 80 311 31.8%
Intermedics 21 0 0 21
19 0 0 19 90.5%
Medtronic 449 182 267 898
181 78 97 356 39.6%
St. Jude Medical 625 388 526 1539
94 85 116 295 19.2%
Sorin ELA 10 144 4 158
1 48 0 49 31.0%
Total
Devices 2158 1340 1284 4782
Replaced 557 455 316 1328
% Replaced 25.8% 34.0% 24.6% 27.8%
Cameron Health 99 99
11 11 11.1%
ICD, implantable cardioverter defibrillator; VVI, single-chamber ICD; DDD,
dual-chamber ICD; CRT, cardiac resynchronization therapy ICD.
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Figure 2 Comparison of longevity according to manufacturers
(total n ¼ 4881, before 2006 n ¼ 2198, after 2006 n ¼ 2683).
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St. Jude Medical (5–5.4 and 5–5.8 years, respectively), with Bio-
tronik being at the tail end (4.6–4.7 years). Sorin ICDs were
incorporated in only one study. Even though these studies are
not without their merits, one of their major limitations lies in
the very skewed range of implant shares of the different manufac-
turers [6–61% in (10), 6–49% in (15), 18–49% in (12)]. In the
present study, with the largest numbers of ICDs implanted, this
range was much smaller (20–34%), which makes this analysis
more robust.
As one can appreciate by looking at data of longevity analysed ei-
ther by lumping together all ICDs of different manufacturers or by
comparing manufacturers in a given pacing mode independent of
time, they often do not reflect the whole truth. In our study, for ex-
ample, Kaplan–Meier analysis suggests that Biotronik CRT-Ds have
by far the best performance, but the analysis with regard to tem-
poral trends gives another picture. Here, Biotronik is in the range
of Medtronic and by far behind Boston Scientific. The poor per-
formance of most Medtronic and Boston Scientific CRT-Ds in the
first half of the study period leads to this distorted result.
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Figure 3 Comparison of longevity of VVI-ICDs manufacturers
(total n ¼ 2158, before 2006 n ¼ 985, after 2006 n ¼ 1272).
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Figure 4 Comparison of longevity of DDD-ICDs manufacturers
(total n ¼ 1340, before 2006 n ¼ 816, after 2006 n ¼ 524).
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Temporal trends
The comparison of longevity at 6 years of ICDs implanted before and
after 2006 shows first and foremost an absolute increase in longevity
of 10% (DDD) and 20% (VVI & CRT), yet differences between man-
ufacturers exist regarding absolute values. In contemporary
VVI-ICDs, Boston Scientific excelled with 100% longevity at 6 years,
Biotronik was subprime with ,50% longevity, and the other manu-
facturers were satisfactory. In DDD pacing mode, Biotronik and
St. Jude Medical were subprime, Sorin and Medtronic moderate,
and again Boston Scientific excelled. The most remarkable difference
was seen in CRT-Ds, with Boston Scientific again showing an almost
100% longevity at 6 years compared with all other manufacturers
with St. Jude Medical being at the tail end with only 26% longevity.
This poor performance seems at first glance contradictory to data
from the study of Alam et al.10 in which St. Jude Medical longevity at
4 years was reported as 92%. At second glance, these results are
hampered as they depend only on 57 implanted CRTs and actually
four replacements.
Temporal trends have been analysed with a cut-off in the year
2002.13,15,18 In two studies,13,15 no significant improvement was ob-
servable. In one study,18 mean longevity of replaced devices im-
proved by 12 months in DDD and CRT and by 20 months in VVI
pacing mode. The value of these results is altogether hampered
by a severe dysbalance between groups (only 12% of ICDs were im-
planted before 2002).
The difference among manufacturers in the second half of the
study period and the striking improvement in longevity in all Boston
Scientific ICD pacing modes might be due to their specific battery
technology. Boston Scientific incorporates a Lithium Manganese
battery with a capacity of almost 2 ampere-hours in their contem-
porary devices, whereas other manufacturers usually use Lithium
Silver Vanadiumwith less ampere-hours. Further studies are needed
to confirm or repudiate this hypothesis.
Longevity and survival
Only one paper described the interrelation of longevity and sur-
vival.12 In 2005, Hauser reported a 4-year survival of 79% and refers
to unpublished data with 4-year longevity of 54%. While survival is
pretty similar to the present study (here 83.3%), a huge difference
exists regarding longevity (here 85.1%). This can be explained, at
least in part, by the temporal trend of increased longevity. However,
it is intriguing that also in newer ICDs, 5-year survival is still better
than 5-year longevity.While the difference was only 5% in VVI-ICDs
(and thus acceptable), it rose to 15% in DDD-ICDs. In CRT-ICDs
implanted in an admittedly high-risk population with a higher mor-
tality, the difference was 23%. This indicates that a better battery
technology is foremost required for this group of patients.
Impact of the number of shocks, pacing
percentage, and pacing thresholds
We could not perform special analyses with regard to these possible
confounders as they were available only in a minority of devices.
Previous studies15,18 negated a significant influence of shocks on lon-
gevity. Pacing percentage and thresholds have been shown to be dif-
ferent in between manufacturers, but only when all ICDs were
grouped together and not in different pacing modes.15 Predictors
of decreased longevity were the LV output per se,10 an increase
in overall pacing output of 1 V,18 and a 10% increase in pacing
percentage,13,18 but no analyses were performed to show that
they were different among manufacturers. A limitation of these ana-
lyses is the fact that only values determined at last follow-up were
considered, thus giving a skewed picture of reality with the use of
a random point in time. In addition, all these possible confounders
probably are smoothed by the large number of devices included
in the present study.
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Figure 5 Comparison of longevity of CRT-ICDs (total
n ¼ 1284, before 2006 n ¼ 397, after 2006 n ¼ 887).
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Limitations
This study has the inherent limitations of all registry data. An attri-
bution bias (the physician could implant a presumed long-lasting
ICD in a young patient and vice versa) might be present but is limited
by the two-centre design of the study and consequently different
perceptions and daily practice. Implantable cardioverter defibrilla-
tors were replaced at ERI and longevity calculated according to it
and not to the end of life of the battery, thus reducing the real lon-
gevity. However, this was done in all studies on longevity so far. As
all ICDs implanted in both centres were included over a long period
of time, some results do not reflect longevity of currently available
and implanted ICDs. However, this is overcome in part by the sep-
arate analysis on temporal trends according to the median time of
implant. If one wants to have data on longevity of rather long-lasting
devices, requesting results that reflect longevity of ICDs implanted
in the past few years is an obvious oxymoron.
Conclusion
At 5 years, overall ICD longevity is 70% and thus lower than the pa-
tient survival of 80%. A highly significant improvement of longevity
was seen in more contemporary models implanted after 2006.
However, this improvement was unequal among the manufacturers.
Results might impact on device selection.
Supplementary material
Supplementary material is available at Europace online.
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Table 3 Comparison of longevity of devices implanted until December 2005 and thereafter (highlighted is the best
performance in the corresponding group) according to the manufacturer and pacing mode
Before 2006 Thereafter
5-year longevity (%) 6-year longevity (%) 5-year longevity (%) 6-year longevity (%)
All ICD models
All manufacturers** 63.9 44.9 80.6 61.6
Biotronik** 44.0 10.5 81.4 42.1
Boston** 65.1 45.7 98.0 98.0
Medtronic|| 77.7 64.1 85.8 72.6
St. Jude Medical** 64.3 49.8 74.1 60.7
Sorin|| 59.8 27.8 77.5 77.5
Intermedics 0 0 n.a. n.a.
Cameron Health n.a. n.a. 47.9 n.a.
VVI
All manufacturers** 73.7 56.4 92.1 76.0
Biotronik** 59.8 15.2 89.1 45.6
Boston** 74.3 53.3 100.0 100.0
Medtronic|| 86.7 80.1 91.7 85.9
St. Jude Medical** 70.9 60.1 94.3 92.6
Sorin n.a. n.a. 80.0 80.0
Intermedics 0 0 n.a. n.a.
Cameron Health n.a. n.a. 47.9 n.a.
DDD
All manufacturers** 58.2 40.8 76.1 50.9
Biotronik** 26.6 4.2 60.0 26.3
Boston# 65.8 52.2 93.3 93.3
Medtronic|| 87.5 68.6 89.3 76.5
St. Jude Medical|| 54.7 46.0 78.7 35.3
Sorin|| 59.8 27.8 n.a. n.a.
CRT
All manufacturers** 47.1 21.2 66.3 43.0
Biotronik** 0 0 76.2 44.9
Boston** 43.5 17.5 97.6 97.6
Medtronic** 39.2 7.4 74.1 46.3
St. Jude Medical|| 61.5 30.9 45.3 26.5
n.a., not applicable, i.e. not manufactured in this period, not implanted in the two hospitals, or time point not reached; ICD, implantable cardioverter defibrillator;
VVI, single-chamber ICD; DDD, dual-chamber ICD; CRT, cardiac resynchronization therapy ICD.
||P ¼ n.s., #P ≤ 0.05, **P ≤ 0.001.
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